Authorized purpose: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.
Clinical role
CT acquisition, reconstruction, visualization, and release-specific examination planning.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or a professional medical society.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: X-ray transmission data taken at different angles and planes.
Who uses it?Intended users: Only trained and qualified users, certified in accordance with country-specific regulations, are authorized to operate the system.
What does the software produce?Output: The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.
What is its most important limitation?Key limitation: The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or a professional medical society.
Clinical takeaway. Clinical role: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.
Evidence takeaway. Evidence from the reviewed source record: K252992 reports system, reconstruction, image-quality, radiation-safety, software, and workflow validation for the listed radiology and large-bore oncology configurations.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.
Exact FDA submission
Checked 2026-09-19
The exact device description states reconstructed cross-sectional DICOM CT images, not the current generalized measurements/planning-dataset list.
The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or a professional medical society.
Exact FDA submission
Checked 2026-09-19
This is the exact packet's explicit low-dose CT lung-screening boundary; the current local-acceptance language is not stated in the packet.
K252992 reports system, reconstruction, image-quality, radiation-safety, software, and workflow validation for the listed radiology and large-bore oncology configurations.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K252992 reports system, reconstruction, image-quality, radiation-safety, software, and workflow validation for the listed radiology and large-bore oncology configurations.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252992 FDA performance package for CT Rembra RT; CT Areta RT; CT Rembra
DesignManufacturer nonclinical CT system, reconstruction, image-quality, safety, and workflow validation
PopulationBroad pediatric and adult diagnostic, oncology, and radiotherapy-planning CT applications
Scopeexact submission
Tested versionCT Rembra RT, CT Areta RT, and CT Rembra release cleared in K252992
IndependenceSponsor or vendor study
K252992
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252992 by exact submission identifier. This does not exclude product-family or later safety information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: X-ray transmission data taken at different angles and planes.
Scope: Exact FDA submission. The exact indications and device description state this acquisition input wording.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.
Scope: Exact FDA submission. The exact device description states reconstructed cross-sectional DICOM CT images, not the current generalized measurements/planning-dataset list.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.
Scope: Exact FDA submission. The exact device description states reconstructed cross-sectional DICOM CT images, not the current generalized measurements/planning-dataset list.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.
Only qualified ct technologists and trained interpreting or treating physicians. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream compatibility acceptance remains required.
Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream compatibility acceptance remains required.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream compatibility acceptance remains required.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact packet classifies the devices as a Computed Tomography X-Ray System and does not state the current CTA modality label. Controlled directory display reconciled from exact FDA wording: Computed Tomography X-Ray System. -> CT/CTA.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: DAFS automatically segments anatomy on DICOM Part 10 CT images and supports reviewed two- and three-dimensional visualization, editing, and area, volume, and intensity measurements; it does not provide diagnostic interpretation.
uCT ATLAS Astound and uCT ATLAS are whole-body CT systems for head, body, cardiac, and vascular imaging, with dual-energy analysis options and protocol-governed low-dose lung-screening use within approved programs.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.